Effectiveness of Maternal Immunization with the RSVPreF3-Mat Vaccine in Preventing Childhood RSV Infection
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on April 15th, 2024
|
Maternal immunization has proven to be an efficient strategy for shielding young children from diseases. RSVPreF3-Mat is a subunit vaccine targeting RSV that has been designed specifically for maternal administration. Its formulation comprises the RSV fusion protein in its prefusion conformation. GlaxoSmithKline, a pharmaceutical company, supported a study aimed at evaluating the efficacy of RSVPreF3-mat in preventing RSV infection among children.
The phase 3 clinical trial enrolled 5328 women aged 18 to 49, each pregnant with a single fetus. Gestational age, confirmed via ultrasonography, ranged from 24 to 34 weeks. Participants were randomly allocated to receive either a placebo or an intramuscular injection containing 120 micrograms of the RSVPreF3-Mat subunit vaccine. Following delivery, the infants underwent monitoring for an additional 6 months. Results indicated that maternal immunization with the RSVPreF3-Mat vaccine conferred a vaccine efficacy of 65.5% against RSV-associated lower respiratory tract infection and 69% against severe manifestations of the infection. However, the use of the maternal vaccine was linked to a 37% increase in the risk of preterm birth. Subsequent analysis revealed a correlation between preterm birth rates and various factors including socioeconomic status and the emergence of the delta variant during the COVID-19 pandemic.
The phase 3 clinical trial enrolled 5328 women aged 18 to 49, each pregnant with a single fetus. Gestational age, confirmed via ultrasonography, ranged from 24 to 34 weeks. Participants were randomly allocated to receive either a placebo or an intramuscular injection containing 120 micrograms of the RSVPreF3-Mat subunit vaccine. Following delivery, the infants underwent monitoring for an additional 6 months. Results indicated that maternal immunization with the RSVPreF3-Mat vaccine conferred a vaccine efficacy of 65.5% against RSV-associated lower respiratory tract infection and 69% against severe manifestations of the infection. However, the use of the maternal vaccine was linked to a 37% increase in the risk of preterm birth. Subsequent analysis revealed a correlation between preterm birth rates and various factors including socioeconomic status and the emergence of the delta variant during the COVID-19 pandemic.